ArticleCancer discovery2020
Gain-of-Function
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.
0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 168 citations in OpenAlex.
- Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- RhoA WT allele loss unleashes the cancer driver function of RhoA E40Q.The Journal of clinical investigation · 2026Article
- Cell differentiation-related signaling pathways: biological functions, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Article
- Implications of Rho GTPase signaling in cancer immunotherapy.Biochemical Society transactions · 2026Review
- Metabolic Signaling Meets Epigenetic Regulation: How Protein Lactylation Remodels the Tumor Immune Microenvironment in Gastric Cancer.Current issues in molecular biology · 2026Review
- Mapping the genetic landscape of hereditary diffuse-type gastric cancer progression.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Integrated spatial transcriptomics and pan-cancer XGBoost modeling uncover spatial drivers of immune exclusion and predict immunotherapy response.Cancer immunology, immunotherapy : CII · 2026Article
- Loss of PRKACB facilitates metastasis of diffuse-type gastric cancer through RhoA signaling activation.Cell death & disease · 2026Article
- Review
- YAP1 Is a Crucial Nexus in the Tumor Microenvironment.Current medical science · 2026Review
- RHOA at the intersection of inflammation-driven and sporadic colorectal cancer.Frontiers in immunology · 2026Review
- Decoding Rho GTPase signalling networks in directed cell migration.Frontiers in cell and developmental biology · 2026Review
- CDH1 reduces endothelial cell permeability by enhancing CDH5 membrane expression under chronic intermittent hypoxia.European journal of medical research · 2025Article
- RHOA regulates mitochondria-ER contact sites through modulation of the VAPB/PTPIP51 tether.Nature communications · 2025Article
- RhoE downregulation leads to enhanced cholesterol biosynthesis and sorafenib resistance in hepatocellular carcinoma.The Journal of biological chemistry · 2025Article
- Integrin CD103 expression in naive CD8Immunity · 2025Article
- CPZ promotes the proliferation of gastric cancer by activating the Wnt pathway through binding with DVL2.Discover oncology · 2025Article
- Urothelial collective-gliding response acts as a toll-like receptor 4-associated defense mechanism.iScience · 2025Article
- Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer.Science advances · 2025Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 8 institutions in 2 countries.
Haisheng Zhang *Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Antje Schaefer *Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID https://orcid.org/0000-0002-2716-9899
Yichen WangDivision of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0001-5730-3019
Richard G HodgeLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID https://orcid.org/0000-0002-1920-1385
Devon R BlakeDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
J Nathaniel DiehlCurriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Alex G PapageorgeLaboratory of Cellular Oncology, NCI, NIH, Bethesda, Maryland.
Matthew D StachlerDivision of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Jennifer LiaoDivision of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Jin ZhouDivision of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Zhong WuDivision of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Fahire G AkarcaDivision of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0003-2254-3279
Leonie K de KlerkDivision of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0002-8034-641X
Sarah DerksDivision of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Mariaelena PierobonCenter for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, Virginia.
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.ORCID https://orcid.org/0000-0002-1216-477X
Timothy C WangDivision of Gastroenterology, Columbia University Medical Center, New York, New York.ORCID https://orcid.org/0000-0001-5730-3019
George ChurchHarvard, MIT, Blavatnik Institute, Wyss Institute, Boston, Massachusetts.
Kwok-Kin WongDivision of Hematology and Oncology, New York University, New York, New York.
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University, Manassas, Virginia.
Adrienne D CoxLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Douglas R LowyDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Channing J Der *Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. adam_bass@dfci.harvard.edu channing_der@med.unc.edu.
Adam J Bass *Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. adam_bass@dfci.harvard.edu channing_der@med.unc.edu.
Dana-Farber Cancer Institute · USUniversity of North Carolina at Chapel Hill · USGeorge Mason University · USBroad Institute · USColumbia University Irving Medical Center · USMassachusetts Institute of Technology · USNational Institutes of Health · USNew York Oncology Hematology · US
Funding
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 2001 to 2026
$36.3MSTRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI LYNN BRY · 1986 to 2026
$32.4MTumor gene expression in vitro and in vivoZIABC008905 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LOWY, DOUGLAS R. · 2009 to 2025
$14.3MCANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0MThe Role of RHOA in Diffuse Gastric CancerR01CA224428 · NCI · DANA-FARBER CANCER INST · PI DER, CHANNING J., WANG, TIMOTHY CRAGIN · 2018 to 2022
$3.6MValidation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancerF30CA243253 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DIEHL, JOHN NATHANIEL · 2019 to 2022
$180kBreaking the paradigm: RhoA as a tumor suppressor in cancerF31CA216965 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLAKE, DEVON R · 2017 to 2018
$57kNCI NIH HHS F30 CA243253NCI NIH HHS F31 CA216965NCI NIH HHS R01 CA224428NCI NIH HHS T32 CA071341NIDDK NIH HHS P30 DK034854NIEHS NIH HHS P30 ES010126
Abstract
Diffuse gastric cancer (DGC) is a lethal malignancy lacking effective systemic therapy. Among the most provocative recent results in DGC has been that of highly recurrent missense mutations in the GTPase RHOA. The function of these mutations has remained unresolved. We demonstrate that RHOA
Indexed as
3T3 CellsAnimalsAntigens, CDCadherinsChlorocebus aethiopsCOS CellsFocal Adhesion Kinase 1Gain of Function MutationGastric MucosaHEK293 CellsHumansMiceProtein Kinase InhibitorsQuinolonesrhoA GTP-Binding ProteinSignal Transduction6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-oneAntigens, CDCadherinsCDH1 protein, humanFocal Adhesion Kinase 1Protein Kinase InhibitorsPTK2 protein, humanQuinolonesrhoA GTP-Binding ProteinRHOA protein, humanSulfones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.